Compare UBCP & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | UBCP | MURA |
|---|---|---|
| Founded | 1902 | 2013 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Major Banks | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.4M | 36.0M |
| IPO Year | N/A | N/A |
| Metric | UBCP | MURA |
|---|---|---|
| Price | $13.82 | $2.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 6.0K | ★ 224.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 6.81% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.31 | N/A |
| Revenue | ★ $30,516,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.59 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | ★ 4.40 | N/A |
| 52 Week Low | $12.25 | $0.95 |
| 52 Week High | $15.64 | $4.74 |
| Indicator | UBCP | MURA |
|---|---|---|
| Relative Strength Index (RSI) | 61.51 | 40.39 |
| Support Level | $13.21 | $2.06 |
| Resistance Level | $14.37 | $2.10 |
| Average True Range (ATR) | 0.37 | 0.01 |
| MACD | 0.06 | -0.01 |
| Stochastic Oscillator | 66.42 | 25.00 |
United Bancorp Inc operates as a bank holding company that provides commercial and retail banking services. Through its subsidiary (Unified Bank), the company provides a broad range of banking and financial services, which includes accepting demand, savings, and time deposits and granting commercial, real estate, and consumer loans. It serves customers in Belmont, Harrison, Jefferson, Tuscarawas, Carroll, Athens, Hocking, and Fairfield counties and the surrounding localities. The bank also operates in Marshall County West Virginia.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.